An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia
A MULTICENTER NON-INTERVENTIONAL STUDY EVALUATING THE BENEFIT OF THE COMBINATION OF MABTHERA (RITUXIMAB) WITH STANDARD CHEMOTHERAPEUTIC REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN HUNGARY
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Budapest, Hungary, 1122
- National Institute of Oncology, A Dept of Internal Medicine
-
Budapest, Hungary, 1083
- Semmelweis University, First Dept of Medicine
-
Budapest, Hungary, 1125
- Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
-
Debrecen, Hungary, 4032
- Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum; III. Belgyogyaszati Klinika
-
Eger, Hungary, 3300
- Markhot Ferenc Oktato Korhaz es Rendelointezet; III. belgyogyaszat
-
Gyula, Hungary, 5700
- Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza; I. Belgyogyaszat-Hematologia Reszle
-
Miskolc, Hungary, 3529
- Miskolci Semmelweis Kórház és Egyetemi Oktatókórház; Haematology Dept.
-
Nyíregyháza, Hungary, 4400
- Josa Andras Korhaz; Ii. Sz. Belgyogyaszati Es Haematologiai Osztaly
-
Pecs, Hungary, 7624
- University of Pecs, I st Dept of Internal Medicine
-
Szeged, Hungary, 6720
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ; Neurológiai Klinika
-
Szolnok, Hungary, 5004
- Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
-
Szombathely, Hungary, 9700
- Vas Megyei Markusovszky Korhaz; Haematologiai Osztaly
-
Székesfehérvár, Hungary, 8000
- Fejér Megyei Szent György Kórház; Hematologiai Osztaly
-
Tatabanuya, Hungary, 2800
- Szent Borbala Korhaz
-
Veszprem, Hungary, 8200
- Veszprem Megyei Csolnoky Ferenc Korhaz Nonprofit Zrt.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosed with first-line CLL having received only 1 cycle of MabThera chemotherapy
- aged >/= 18 years
Exclusion Criteria:
- Pregnant or breast-feeding
- Receipt of an investigational drug within 30 days prior to entering the study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
CLL patients on Mabthera (rituximab)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall response rate (ORR) as assessed by the investigator using routine assessment techniques
Time Frame: 7 months
|
7 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
ORR analysed according to concomitant chemotherapy
Time Frame: 7 months
|
7 months
|
|
ORR analysed according to age
Time Frame: 7 months
|
7 months
|
|
ORR analysed according to CIRS score
Time Frame: 7 months
|
7 months
|
|
ORR analysed according to certain chromosomal abnormalities
Time Frame: 7 months
|
7 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML29201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.